


Small Molecule Program

Diabetes



Key insights

- A small molecule program with selective and efficacious lead compounds on a previously undrugged target, SMNDC1 is developed
- Potential therapeutic application to Diabetes and Cancer
- Smndc1 represses insulin transcription and PDX1 mRNA stability in α cells
- Loss of SMNDC1 in pancreatic human islets improves glucose responsiveness

Intellectual Property

Pharmaceutical composition and method of use claims, EP priority application, 2023

Publications

- Enders et al (2023) Nature Communications
- Casteels et al (2022) Cell Reports

Partnering

• We are seeking development partners: sponsorship, collaborations, licensing

Lead Researcher

Stefan Kubicek - Head, Chemical Epigenetics. Dr. Kubicek studied organic chemistry in Vienna and Zürich. He received his Ph.D. in Thomas Jenuwein's group at the IMP in Vienna followed by postdoctoral work with Stuart Schreiber at the Broad Institute of Harvard and MIT in the U.S. Stefan is a co-founder of startups Proxygen and Solgate.

CeMM

CeMM is an interdisciplinary research institute of the Austrian Academy of Sciences committed to advancing the understanding of human diseases through basic and biomedical research. Located in a tailor-made building in the midst of the campus of the Medical University of Vienna

Partnering: Prudence Donovan – Head of Technology Transfer pdonovan@cemm.at